Nephrocare Health IPO opens; should you apply? Market guru Anil Singhvi decodes

IndiGo under SEBI radar for THIS reason; check share price update

Fresh Turbulence for IndiGo: CCI and Parliamentary panel tighten scrutiny, 10% flight cut ordered

Meesho Share Price: E-commerce stock surges 45% on debut on NSE, BSE – Buy, sell or hold? Anil Singhvi weighs in

Vidya Wires share price opens at Rs 52 on NSE, BSE—Massive subscription, muted listing

Aequs enters listed space at 13% premium; here's what Anil Singhvi suggests

Slight relief in Delhi’s air quality, yet pollution and cold hold firm

India-US trade talks set to resume on Wednesday, first since Trump 2.0 exited record shutdown

Gold & Silver Price Today: MCX outlook with key levels, trading strategy and fresh targets for traders

Stock Market Today: Sensex begins flat, Nifty tests 25,900; IndiGo, JSW Steel top losers

Axis Direct has given a 'buy' rating on Balrampur Chini. The brokerage has given a target of Rs 638 and a stop loss of Rs 560. This means the stock has an upside of 12 per cent from its last closing price.

Axis Direct picks JSW Steel, Balrampur Chini, Biocon and 2 other stocks for 15 days; check out targets and stop losses

Strides Pharma Science's revenue stood at Rs 1,087 crore in the period under review compared to Rs 932 crore in the year-ago quarter, the pharma company said.

Strides Pharma Q1 Results: Net profit at Rs 84 crore vs net loss of Rs 29.5 crore a year ago

Total expenses in the fourth quarter were higher at Rs 984.21 crore as compared to Rs 972.26 crore.The board has recommended a final dividend of Rs 2.50 per equity share of Rs 10 each for the financial year ended March 31, 2024, the filing said.

Strides Pharma reports net profit of Rs 10.44 crore in Q4

Strides Pharma Science on Tuesday said its subsidiary has received approval from the US health regulator to market a generic medication for seizures.

Strides Pharma gets USFDA nod for generic medication

Total income, however, rose to Rs 1,035 crore in the second quarter as compared with Rs 920 crore in the year-ago period, Strides Pharma said in a regulatory filing.

Strides Pharma Science Q2 loss at Rs 149 crore

Strides Pharma Science&nbsp;said its subsidiary has received approval from the US health regulator to market a generic version of Gilead Sciences' Atripla tablets which are indicated to help control HIV infection.

Strides Pharma gets USFDA nod to market HIV drug 

The company's board has approved a scheme of arrangement amongst Strides Pharma Science, Steriscience Specialties and Stelis Biopharma, the drug firm said in a regulatory filing.

 Strides Pharma to demerge CDMO, soft gelatin business into separate entity

Strides Pharma news:&nbsp;Strides Pharma Science announced that its step-down wholly-owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, received USFDA (United States Food and Drug Administration) approval for Icosapent Ethyl Capsules 0.5 gram and 1 gram.&nbsp;

Strides Pharma shares hit 52-week high as company's unit receives USFDA approval for Icosapent Ethyl capsules

Strides Pharma Science share price NSE:&nbsp;Pharmaceutical company Strides Pharma Science shares rallied on Friday for the third straight day and zoomed nearly 12 per cent to clock a fresh 52-week high of Rs 522.75

Strides Pharma Science shares zoom 12% after its arm receives USFDA approval for Dolutegravir tablets

The approval granted by the US Food &amp; Drug Administration (USFDA) is for Mycophenolate Mofetil for oral suspension of strength 200 mg/ml, Strides Pharma Science said in a regulatory filing.

Strides Pharma arm gets USFDA nod for generic Mycophenolate Mofetil oral suspension 

Q3 Results 2023: Uco Bank, Macrotech Developers and Strides Pharma declare December quarter results - HIGHLIGHTS

Consequently, the Nifty50 on Monday ended around the day’s high to close at 17,525 levels. The broader indices also closed with modest gains.

Stocks to buy today: Coal India, Tata Chemicals and Strides Pharma among 20 stocks for profitable trade on August 10

Extending gains for the fourth session, the Indian market ended higher by around one per cent aided by positive global cues.&nbsp;

Buy, Sell or Hold: What should investors do with Strides Pharma, MRPL and IEX shares?

The rise of the Covid-19 variant Omicron has once again brought pharma shares in focus.&nbsp;

Pharma shares in action after Dr Reddy's, Strides Pharma get DCGI nod to launch Molnupiravir

The shares of Strides Pharma and Astral Limited each jumped around 5 per cent to Rs 809.15 and Rs 2134 per share on the BSE intraday trade today as both the stocks made entry into Futures &amp; Options (F&amp;O) space for the August series, as per the exchanges.

Strides Pharma, Astral shares jump 5% on the back of August F&O series entry news– check details here

Zee Business Managing Editor Anil Singhvi said that the reason for taking up this stock today is because investors have not considered whether it may benefit from Covid pandemic. In fact, notably, this stock has not moved the way other pharma companies have moved. Today's SIP stock is Strides Pharma

Anil Singhvi picks Strides Pharma as his 'SIP STOCK' today, know the reason WHY

In a chat with Zee Business Managing Editor Anil Singhvi today, market expert Jay Thakkar recommended his top three mid-cap stock picks for investors to buy, which he said have great potential to earn bumper returns. These stocks were recommended with long-term, positional medium-term, and short-term views. Know why this analyst thinks these stocks hold promise!&nbsp;&nbsp;

Mid-cap Picks with Anil Singhvi: Jay Thakkar picks CCL Products, Andhra Sugars and Strides Pharma for top returns

Players who are late to the chase run the risk of launching when the market is saturated, resources are distributed, and the pandemic is almost over. All want the pandemic to end soon, but this may inversely correlate with research intensity. The smart companies took advantage of COVID-19 to improve efficiency of their research (Junshi) and manufacturing (Strides Pharma) and strengthen their reputation (WuxiBio) through good execution.&nbsp;

WuxiBio, Cadila Healthcare, Junshi to Strides Pharma, Macquarie highlights Global fight against Covid-19 pandemic

strides-pharma

Axis Direct has given a 'buy' rating on Balrampur Chini. The brokerage has given a target of Rs 638 and a stop loss of Rs 560. This means the stock has an upside of 12 per cent from its last closing price.

Strides Pharma Science's revenue stood at Rs 1,087 crore in the period under review compared to Rs 932 crore in the year-ago quarter, the pharma company said.

Total expenses in the fourth quarter were higher at Rs 984.21 crore as compared to Rs 972.26 crore.The board has recommended a final dividend of Rs 2.50 per equity share of Rs 10 each for the financial year ended March 31, 2024, the filing said.

Strides Pharma Science on Tuesday said its subsidiary has received approval from the US health regulator to market a generic medication for seizures.

Total income, however, rose to Rs 1,035 crore in the second quarter as compared with Rs 920 crore in the year-ago period, Strides Pharma said in a regulatory filing.

Zee Business

Home

Personal Finance

India

Economy

Tech

Auto

Markets

Jobs

Indian Railways

World

Videos

Photos

Strides Pharma News- Zee Business provides latest news on Strides Pharma, Strides Pharma news Today, Top News on Strides Pharma, update on Strides Pharma Stay updated with business news, breaking news headlines.

Strides Pharma Latest News- Top News on Strides Pharma, Update on Strides Pharma, Strides Pharma News Today, Breaking News Headlines, Business News | Zee Business

Strides Pharma

Axis Direct picks JSW Steel, Balrampur Chini, Biocon and 2 other stocks for 15 days; check out targets and stop losses

Strides Pharma Q1 Results: Net profit at Rs 84 crore vs net loss of Rs 29.5 crore a year ago

Strides Pharma reports net profit of Rs 10.44 crore in Q4

Strides Pharma gets USFDA nod for generic medication

Strides Pharma Science Q2 loss at Rs 149 crore

Strides Pharma gets USFDA nod to market HIV drug

RECOMMENDED

Nephrocare Health IPO opens; should you apply? Market guru Anil Singhvi decodes

IndiGo under SEBI radar for THIS reason; check share price update

Fresh Turbulence for IndiGo: CCI and Parliamentary panel tighten scrutiny, 10% flight cut ordered

Meesho Share Price: E-commerce stock surges 45% on debut on NSE, BSE – Buy, sell or hold? Anil Singhvi weighs in

Vidya Wires share price opens at Rs 52 on NSE, BSE—Massive subscription, muted listing

Aequs enters listed space at 13% premium; here's what Anil Singhvi suggests

Slight relief in Delhi’s air quality, yet pollution and cold hold firm

India-US trade talks set to resume on Wednesday, first since Trump 2.0 exited record shutdown

Gold & Silver Price Today: MCX outlook with key levels, trading strategy and fresh targets for traders

Stock Market Today: Sensex begins flat, Nifty tests 25,900; IndiGo, JSW Steel top losers

Strides Pharma to demerge CDMO, soft gelatin business into separate entity

Strides Pharma shares hit 52-week high as company's unit receives USFDA approval for Icosapent Ethyl capsules

Strides Pharma Science shares zoom 12% after its arm receives USFDA approval for Dolutegravir tablets

Strides Pharma arm gets USFDA nod for generic Mycophenolate Mofetil oral suspension

Q3 Results 2023: Uco Bank, Macrotech Developers and Strides Pharma declare December quarter results - HIGHLIGHTS

Stocks to buy today: Coal India, Tata Chemicals and Strides Pharma among 20 stocks for profitable trade on August 10

Buy, Sell or Hold: What should investors do with Strides Pharma, MRPL and IEX shares?

Pharma shares in action after Dr Reddy's, Strides Pharma get DCGI nod to launch Molnupiravir

Strides Pharma, Astral shares jump 5% on the back of August F&O series entry news– check details here

Anil Singhvi picks Strides Pharma as his 'SIP STOCK' today, know the reason WHY

Mid-cap Picks with Anil Singhvi: Jay Thakkar picks CCL Products, Andhra Sugars and Strides Pharma for top returns

WuxiBio, Cadila Healthcare, Junshi to Strides Pharma, Macquarie highlights Global fight against Covid-19 pandemic

Top News

Nephrocare Health IPO opens; should you apply? Market guru Anil Singhvi decodes

IndiGo under SEBI radar for THIS reason; check share price update

Fresh Turbulence for IndiGo: CCI and Parliamentary panel tighten scrutiny, 10% flight cut ordered

Meesho Share Price: E-commerce stock surges 45% on debut on NSE, BSE – Buy, sell or hold? Anil Singhvi weighs in

Vidya Wires share price opens at Rs 52 on NSE, BSE—Massive subscription, muted listing

Aequs enters listed space at 13% premium; here's what Anil Singhvi suggests